Manal F. Abdelmalek, MD

Professor of Medicine
Campus mail 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone (919) 684-3262
Email address manal.abdelmalek@duke.edu

My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
  • Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
  • M.D., University of Missouri Kansas City, School of Medicine, 1992

Grants

Publications

Francque, Sven, Gyongyi Szabo, Manal F. Abdelmalek, Christopher D. Byrne, Kenneth Cusi, Jean-François Dufour, Michael Roden, Frank Sacks, and Frank Tacke. “Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.” Nat Rev Gastroenterol Hepatol, October 22, 2020. https://doi.org/10.1038/s41575-020-00366-5.

PMID
33093663
Full Text

Glass, Oliver, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, et al. “Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.” Journal of Hepatology 73, no. 3 (September 2020): 680–93. https://doi.org/10.1016/j.jhep.2020.04.030.

PMID
32353483
Full Text

Wegermann, Kara, Ayako Suzuki, Alisha M. Mavis, Manal F. Abdelmalek, Anna Mae Diehl, and Cynthia A. Moylan. “Tackling NAFLD: Three Targeted Populations.” Hepatology, August 31, 2020. https://doi.org/10.1002/hep.31533.

PMID
32865242
Full Text

Garcia-Tsao, Guadalupe, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, et al. “Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.” J Hepatol 72, no. 5 (May 2020): 885–95. https://doi.org/10.1016/j.jhep.2019.12.010.

PMID
31870950
Full Text

Eslam, Mohammed, Arun J. Sanyal, Jacob George, and Jacob International Consensus Panel. “MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.” Gastroenterology 158, no. 7 (May 2020): 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

PMID
32044314
Full Text

Rinella, Mary E., Michael Allison, Philippe Mathurin, Eric Lawitz, Quentin M. Anstee, Ingolf Schiefke, Salvatore Petta, et al. “OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY.” In Gastroenterology, 158:S1406–7, 2020.

Scholars@Duke

Francque, Sven M., Alexander Hodge, Jerome Boursier, Sam Moussa, Ziad H. Younes, Grace S. Park, Gerardo Rodriguez, et al. “LONG-TERM SAFETY PROFILE OF CENICRIVIROC IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS: ROLLOVER STUDY.” In Gastroenterology, 158:S1446–47, 2020.

Scholars@Duke

Chalasani, Naga, Manal F. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, et al. “Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.” Gastroenterology 158, no. 5 (April 2020): 1334-1345.e5. https://doi.org/10.1053/j.gastro.2019.11.296.

PMID
31812510
Full Text

Liu, Xue-Jing, Li Xie, Kuo Du, Chang Liu, Ning-Ping Zhang, Chen-Jian Gu, Ying Wang, et al. “Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.” Liver Int 40, no. 4 (April 2020): 830–43. https://doi.org/10.1111/liv.14370.

PMID
31903720
Full Text

Anstee, Quentin M., Brent A. Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F. Abdelmalek, Zobair M. Younossi, Jiacheng Yuan, Maria Lucia Pecoraro, et al. “Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.” Contemp Clin Trials 89 (February 2020): 105922. https://doi.org/10.1016/j.cct.2019.105922.

PMID
31881392
Full Text

Pages